To assess the impact of antiviral prophylaxis during the first 3 months after transplantation on the frequency, timing, and outcome of cytomegalovirus (CMV) pneumonia during the first year, 541 adult allogeneic blood and marrow transplant recipients were evaluated. Thirty-four patients (6.3%) developed 35 episodes of CMV pneumonia at a mean of 188 days after transplantation, with an associated mortality rate of 76%. Twenty-six episodes (74%) occurred late (after day 100). Of the patients with late CMV pneumonia almost all (92%) had chronic graft vs. host disease or had received T cell -depleted transplants. Fourteen late CMV pneumonias (54%) were associated with serious concurrent infections, and 100% of these episodes were fatal. In conclusion, although the frequency of CMV pneumonia in the early posttransplantation period may be substantially reduced by prophylaxis, CMV continues to be a major cause of morbidity and mortality in the late period. Some subsets of patients need more prolonged surveillance and prophylaxis and/or preemptive therapy.
Cytomegalovirus (CMV) pneumonia is a major cause of of CMV-specific T cell lymphocyte responses and thereby promote the occurrence of late CMV pneumonia [14, 18] . morbidity and mortality in allogeneic blood and marrow transplant recipients [1 -3] . In the absence of effective prophylaxis At The University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, a universal prophylaxis strategy was and therapy, CMV pneumonia has been reported to occur in 12% to 20% of patients, with an associated mortality rate of evaluated. To assess the impact of administering ganciclovir prophylaxis during the first 3 months after transplantation on ú85% [1, 4 -6] .
There are currently two widely used strategies for preventing the frequency, timing, and outcome of CMV pneumonia during the first year, we reviewed our experience with adult allogeneic CMV pneumonia in these patients [7 -17] . One strategy involves preemptive therapy for subclinical CMV infections, blood and marrow transplant recipients. identified by detection of CMV in blood or bronchoalveolar lavage fluid. This strategy has the advantage that it targets Methods patients with subclinical CMV disease but the disadvantage Patients with CMV pneumonia were identified by reviewing that 12% -29% of patients present with CMV pneumonia and the medical and virology records and the autopsy reports for no prior detection of the virus. The other strategy involves the patients at least 17 years old who underwent allogeneic blood administration of antiviral prophylaxis to all patients during or marrow transplantation at MDACC between May 1992 and the period of highest risk, which operationally has generally May 1996. extended until Ç3 months after transplantation. This strategy During the study period, specimens for surveillance shell has the advantage of providing more effective prophylaxis but vial and conventional blood cultures for CMV were obtained requires administration of relatively toxic drugs for a prolonged weekly from 10 days before transplantation until 100 days after time to the entire patient population. In addition, ganciclovirtransplantation. After day /100, blood specimens for CMV induced neutropenia may increase the risk of bacterial and cultures were obtained only from symptomatic patients. Most fungal infections. Recent reports have further suggested that patients with lower respiratory tract illnesses underwent bronprolonged ganciclovir prophylaxis may inhibit the development choscopy.
Definitions. CMV viremia was defined as isolation of CMV from blood by shell vial or conventional culture. CMV pneumonia was defined as identification of CMV in a lung tissue (4) 3 (75) sponsive to growth factors, foscarnet was administered intrave-MDS 2/28 (7) 2 (100) nously at 60 mg/kg q8h.
Statistical analysis was performed by using the x 2 test and a two-tailed Fisher's exact test for examination of differences NOTE. ALL Å acute lymphocytic leukemia; AML Å acute myelogenous leukemia; BM Å bone marrow; CML Å chronic myelogenous leukemia; CMV in proportions. A P value of õ.05 was considered to be statisti-Å cytomegalovirus; MDS Å myelodysplastic syndrome; PBSC Å peripheral cally significant. blood stem cell.
* BM transplant vs. PBSC transplant, P õ .05; differences between other parameters were not statistically significant.
Results † Chronic lymphocytic leukemia (23 patients), aplastic anemia (22), breast cancer (7), multiple myeloma (7), and other types of leukemia (7).
From May 1992 to May 1996, 541 adults received an allogeneic blood or marrow transplant at The University of Texas M. D. Anderson Cancer Center. During the first year after transral prophylaxis was being administered. In contrast, 25 patients (5%) developed 26 episodes of CMV pneumonia after day plantation, 34 patients (6.3%) developed 35 episodes of CMV pneumonia. The frequency of CMV pneumonia varied by diag-/100, after the discontinuation of antiviral prophylaxis; the mean day of onset was day /237 (range, day /115 to day nosis and ranged from 4% among patients with lymphoma to 11% among patients with chronic myelogenous leukemia and /365). The mortality rate associated with CMV pneumonia was from 5% among bone marrow transplant recipients to 10% among peripheral blood stem cell (PBSC) transplant recipients similarly high in the different periods (50%, 86%, and 73%, respectively) (table 3) . Irrespective of the time of occurrence (P õ .05) (table 1). The mortality rate associated with CMV pneumonia was high (76%) and similar among the different after transplantation, CMV pneumonia was associated with a mortality rate of 100% if therapy was initiated after respiratory subsets of patients. The characteristics of the patients with CMV pneumonia and the time of occurrence of the pneumonias failure requiring support with mechanical ventilation (table 4) . The mortality rate was 68% if therapy was initiated at least 24 after transplantation, respectively, are shown in tables 2 and 3. The mean day of onset of CMV pneumonia was day /188 hours before respiratory failure requiring support with mechanical ventilation. (range, day /20 to day /365).
There were relatively few episodes of CMV pneumonia durEvaluation for potential risk factors for CMV pneumonia revealed the following for the 25 patients with 26 late episodes ing the preengraftment period and during the period of antiviral prophylaxis before day /100. Only one patient (0.2%) develof CMV pneumonia: 8 (32%) had matched unrelated donors (6) or mismatched related donors (2); 10 (40%) had received oped CMV pneumonia during the preengraftment period before the initiation of ganciclovir prophylaxis. This patient had acute T cell -depleted marrow transplants and antithymocyte globulin; 12 (48%) had received total body irradiation; 11 (44%) myelogenous leukemia and had received a marrow transplant from a matched unrelated donor without T cell depletion. Only had had acute graft vs. host disease (GVHD) grades 2 -4; 16 (64%) had extensive chronic GVHD; and 14 (56%) had precedseven patients (1.3%) developed CMV pneumonia during the classical high-risk period (day /30 to day /100) when antiviing viremias. Overall, 23 patients with late CMV pneumonia / 9c63$$mr05 02-22-99 13:48:13 cida UC: CID are being closely monitored and aggressively treated for sub-GVHD prophylaxis clinical infections [7 -17] . As demonstrated in this study and Cyclosporine 25 19 earlier investigations [7 -17] , the frequency of CMV pneumo- Tacrolimus  9  6 nia in the first 100 days after transplantation can be significantly In the current study, 74% of the episodes of CMV pneumonia occurred 100 days after transplantation. The mean day of onset NOTE. The mean age in y (range) and the male-to-female ratio were as of CMV pneumonia was delayed to day /188, compared with follows: all patients, 41 (17 -60) and 21:13, respectively; and patients with late CMV pneumonia, 41 (17 -55) and 17:8, respectively. Abbreviations: ALL Å acute lymphocytic leukemia; AML Å acute myelogenous leukemia; BM Å bone marrow; CML Å chronic myelogenous leukemia; CMV Å cytomegalovi- Table 3 after receiving two marrow transplants from matched unrelated donors, and the other had relapse of lymphoma after receiving NOTE. One patient with chronic myelogenous leukemia who had received a T cell -depleted bone marrow transplant from a mismatched related donor a PBSC transplant from a matched related donor.
had two episodes of late CMV pneumonia occurring at day /177 and day Fourteen (54%) of the 26 late CMV pneumonias were associ-/324, respectively, the latter of which was fatal. The differences between ated with serious concurrent pulmonary infections including CMV pneumonia -associated deaths during different periods after transplantation were not statistically significant. Abbreviation: CMV Å cytomegalovirus.
the following: Pseudomonas aeruginosa pneumonia (5) historical controls of days /50 to /60 [1, 3, 20] . The overall ceived ganciclovir prophylaxis at engraftment was lower before day 100 (2.5% vs. 14%, respectively) but higher after day 100 frequency of late CMV pneumonia of 5% that was observed in this study is an underestimate of the actual risk for allogeneic (13.4% vs. 6.1%, respectively) than that among patients who received intermittent CMV pp65 antigenemia -guided preemptransplant recipients who are seropositive before transplantation and/or have a seropositive donor, since Ç15% of our tive ganciclovir therapy [14] . The higher frequency of late CMV disease among patients receiving ganciclovir prophylaxis allogeneic transplant recipients were CMV-seronegative before transplantation and had a seronegative donor. Although these at engraftment was thought to reflect their significantly greater exposure to ganciclovir with a resulting suppression of CMV patients did not receive antiviral prophylaxis, they were at low risk (õ3%) for CMV disease since they received CMVreactivation and inhibition of immunologic recovery. Of interest, there was no significant difference in survival and CMV seronegative or leukocyte-depleted blood products [21] . In this study, none of these seronegative patients at risk for primary disease -related mortality between these two strategies.
In spite of standard therapy with ganciclovir and intravenous CMV disease developed CMV pneumonia within the first year after transplantation.
immune globulin [29 -32] , late CMV pneumonia continued to be associated with a high mortality rate ranging from 67% to The 5% frequency of late CMV pneumonia is also an underestimate, since Ç25% of these high-risk patients die before 100 100%, depending on whether therapy was initiated before or after the onset of respiratory failure requiring support with days after transplantation [22] and since CMV pneumonias may not always be accurately diagnosed in the late transplantation mechanical ventilation. Approximately 20% of the late pneumonias were recognized only after the onset of respiratory period when patients often return home to their local communities and are no longer being intensively monitored. The higher failure. The high mortality rate associated with late CMV pneumonia with currently available therapies underscores the need frequency of CMV pneumonia among PBSC transplant recipients than among marrow transplant recipients in our study is to diagnose and treat subclinical CMV infections before the development of pneumonia. It is also possible that the virus noteworthy but warrants further investigation in view of recent conflicting reports regarding the frequency of CMV infection may have developed resistance to ganciclovir or foscarnet during prolonged exposure to these drugs [33 -37] . The need for and disease among PBSC transplant recipients [23] [24] [25] .
The high frequency of CMV pneumonia and associated opantiviral drug susceptibility testing to guide therapy is evident. Whether a combination of antiviral drugs would have been portunistic infections in the late transplantation period highlights the persisting profound immunodeficiency in some submore effective remains to be determined. Approximately 50% of the late CMV pneumonias were assosets of these patients, all but two of whom in our study had extensive chronic GVHD and/or had received a T cell -depleted ciated with serious concurrent opportunistic infections, a finding suggesting that these patients had an underlying profound marrow transplant. The high frequency of late CMV pneumonia may also have reflected a delayed reconstitution of CMV-speimmunodeficiency that was perhaps intensified by the immunosuppressive effects of the CMV infection itself. Among these cific T lymphocyte immunity in the setting of prolonged ganciclovir prophylaxis [18, 26 -28] . Clinical support for this hypatients, the mortality rate was 100%. This result suggests that an effective strategy may necessitate measures to enhance the pothesis has recently been provided by a study demonstrating that the incidence of CMV disease among patients who reunderlying immunity as well as more effective antiviral ther-/ 9c63$$mr05 02-22-99 13:48:13 cida UC: CID
